Navigation Links
Updated data on novel HPV vaccine confirms efficacy in large population

Updated data from a study on a promising new vaccine against a pre-cancerous cervical virus shows superior efficacy in preventing cervical pre-cancers and non-invasive cervical cancer, according to a study presented today during the American Association for Cancer Research's 4th Annual Frontiers in Cancer Prevention Research meeting in Baltimore.

Final results of the phase III study, originally published in early October, confirmed the vaccine's efficacy from available combined phase II and phase III data sets, incorporating an additional 7,000 patient records as compared to the interim results. The researchers concluded from these analyses that the administration of this vaccine, known as GARDASIL, is highly effective in preventing high-grade pre-cancerous illnesses and non-invasive cervical cancers.

Of the 8,487 women who received the vaccine, none were diagnosed with high-grade cervical pre-cancers (CIN 2/3+, cervical intraepithelial neoplasia) or non-invasive cervical cancers associated with human papillomavirus (HPV) types 16 and 18. Of the 8,460 women who did not receive the vaccine, 53 such cases were diagnosed.

In the larger population analysis, which included women who may have become infected with HPV during the vaccination period or who may have violated the protocol (e.g. by missing visits, etc.), the vaccine prevented 99 percent of HPV 16 or 18-related high-grade cervical pre-cancers (1 of 9,342 pts versus 81 of 9,400 in the placebo group) with an average follow up of 25 months.

The vaccine was generally well tolerated, and the most common adverse event reported in the trial was local discomfort at the injection site.

The study is part of an ongoing phase III program involving more than 25,000 people in 33 countries. For the FUTURE II study, a prospective, randomized, double-blind, placebo-controlled study, women aged 16 to 26 years were randomized to receive a three-dose regimen of either the vaccine
'"/>

Source:American Association for Cancer Research


Page: 1 2

Related biology news :

1. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
2. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
3. GeneNotes - A novel information management software for biologists
4. Endocannabinoids ?the brains cannabis ?demonstrate novel modes of action to stress
5. A novel virus for croup
6. Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses
7. A novel method to measure circadian cycles
8. UCSD discovery may provide novel method to generate medically useful proteins
9. Neurons generated in the adult brain learn to respond to novel stimuli
10. Federal grant funds research on novel HIV therapy
11. Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Updated data novel HPV vaccine confirms efficacy large population

(Date:5/23/2013)... mechanism by which estrogen suppresses lipid synthesis in the ... approach toward treating certain liver diseases. , With ... are changing long-held views in the field. Study results ... Science Signaling . , "The dogma in the ... only receptors located in the nucleus respond to steroid ...
(Date:5/23/2013)... unnecessarily undergo surgery or harsh treatments because science ... aggressive forms of the disease. Researchers at Case ... are developing technology that allows patients to safely ... treatments or take drastic measures. , The project ... professor of biomedical engineering at Case Western Reserve ...
(Date:5/23/2013)... of the world are billions of animal and plant ... and grasses, all stacked, stored and preserved in jars ... could be critical to understanding how the Earth,s biodiversity ... footprint if only the information were easily accessible. ... the help of a team from the University of ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... . . Changing the behavior of a material ... the computing power of Oak Ridge National Laboratory,s Jaguar supercomputer, ... and hydrogen to nanoribbons made of boron nitride. The added ... insulator into that of a metal. That makes ...
... hot springs are furthering efforts at the Department of ... from crops such as switchgrass. The ... expensive enzymes that break down complex plant materials to ... cheaper alternative is consolidated bioprocessing, a streamlined process that ...
... study is revealing new information about a key protein,s ... neurological disorders. This work could one day lead to ... associate professor in The University of Texas at Dallas, ... with senior neuroscience student Francisco Garcia on a series ...
Cached Biology News:ORNL story tips, February 2012 2ORNL story tips, February 2012 3ORNL explores proteins in Yellowstone bacteria for biofuel inspiration 2Study looks at possible link to hyper-excitability factors in epilepsy, autism and more 2
(Date:5/24/2013)... SAN DIEGO , May 24, 2013 ... a  company using proprietary taste science technologies to discover, ... David Linemeyer , Ph.D., the Company,s ... , Vice President, Investor Relations & Corporate Communications, will ... Friday, May 31, at 10:25 a.m. Eastern Time (7:25 ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... IL-8 and Future ... in Cancer and Inflammation, COPENHAGEN, September 13 ... antibody is directed,to IL-8 (interleukin-8) and may have potential ... studies to treat glioblastoma,a cancer of the central nervous ...
... - Physicians Welcome New Option ... has a Rapidly Bactericidal Mode of Action ... treatment of both,methicillin-sensitive and resistant Staphylococcus aureus ... infections (right-sided,infective endocarditis) has been announced today ...
... Named 2007 Medical Products Industry Leader, DEERFIELD, Ill., ... announced today that it has been named 2007,Medical Products ... World) and the Dow Jones Sustainability North America Index,(DJSI ... the,company has been listed in the DJSI and the ...
Cached Biology Technology:Genmab Discloses Target and Development Plans for HuMax-Inflam 2Genmab Discloses Target and Development Plans for HuMax-Inflam 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year 2
Human Cell Line Slides...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
Biology Products: